Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $32.44, but opened at $30.88. Ascentage Pharma Group International shares last traded at $30.88, with a volume of 289 shares traded.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. BTIG Research started coverage on shares of Ascentage Pharma Group International in a research note on Monday, November 10th. They issued a “buy” rating and a $50.00 price objective for the company. Truist Financial set a $51.00 price objective on Ascentage Pharma Group International in a research report on Monday, November 24th. Oppenheimer assumed coverage on Ascentage Pharma Group International in a research note on Thursday. They set an “outperform” rating and a $45.00 target price for the company. Finally, Piper Sandler started coverage on Ascentage Pharma Group International in a research report on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 price target on the stock. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $48.50.

Ascentage Pharma Group International Trading Up 3.8%

The business has a 50 day moving average of $34.57 and a 200-day moving average of $36.39. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors and hedge funds have recently bought and sold shares of the business. Monashee Investment Management LLC acquired a new stake in Ascentage Pharma Group International during the 1st quarter worth $3,511,000. Chevy Chase Trust Holdings LLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter worth about $227,000. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the second quarter worth about $391,000. Tema Etfs LLC acquired a new position in Ascentage Pharma Group International in the 2nd quarter valued at about $610,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Ascentage Pharma Group International in the 3rd quarter valued at about $96,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.